Chemotherapy-Induced Nausea and Vomiting (CINV)
A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. Cancer Management and Research. Mason JW et al.
Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron. Journal of Experimental Pharmacology. Ottoboni TB et al.
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Supportive Care in Cancer. Raftopoulos H et al.